IB Net Payout Yields Model

C3.ai: Trough Quarter

Update - Apr. 4, 2023

The short attack is here with Kerrisdale Capital attacking the accounting of C3.ai right after the stock soars into the quarter end. The stock already wasn't as appealing back above $30. The accounting questions appear a stretch, but the company has regularly replaced the CFO in the last 4 years. 

  • C3.ai (NYSE:AI) fell 12% after Kerrisdale Capital, which released a short report on the company last month, wrote a letter to the company's auditor outlining its concerns.
  • Kerrisdale, run by Sahm Adrangi, sent a letter to Deloitte & Touche, highlighting its concerns with alleged accounting

Finviz Chart


Update - Apr. 2, 2023

C3.ai had a huge rally to end March likely due to fund managers piling into the stock to report a position at quarter end. The move appears silly but the stock is officially in breakout mode above $30 here. Even SoundHound Ai (SOUN) rallied 40% on Friday.  

  • C3.ai (NYSE:AI) shares surged by more than 21% Friday as investors poured into the artificial intelligence stock on the last day of the first quarter of the year.
  • More than 61M shares of C3.ai (

 Finviz Chart

Original article posted on March 3. 

  • C3.ai, Inc. reported a solid earnings beat, though revenues dipped 5% from last year.
  • The enterprise AI software company made great progress in shifting to the consumption-based pricing model, with strong growth in customers and pilot programs.
  • The stock is still relatively cheap at a forward EV/S multiple below 6x, but investors shouldn't chase C3.ai higher on hype.
C3.ai, Inc. (NYSE:AI) just reported a quarter where revenues fell YoY, yet the stock is soaring. The enterprise AI software company has jumped with all of the generative AI chat hype, but C3.ai reported a trough revenue quarter, likely sending

Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 

Comments

Popular posts from this blog

Aurora Cannabis: Deal Or No Deal

Celsius: Unaltered Growth Story

Hims & Hers Health: Still Firing On Strong Cylinders